BioSpace News Archive

Sun Pharmaceutical Industries Limited announced results from a Phase 1, multiple ascending-dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034 in obese adults.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, presented new real-world insights from a survey on Tandem Mobi user satisfaction and wearability during the 84th Scientific Sessions of the American Diabetes Association taking place in Orlando, Florida.

Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis, on cardioinflammatory lipids at the American Diabetes Association’s 84th Scientific Sessions.

The American Diabetes Association ® announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potential funders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers.

MannKind Corporation announced positive 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza® vs. usual care, an automated insulin delivery system, or a pump without automation) utilizing a higher initial conversion dose from mealtime injectable insulin to inhaled insulin.

Takeda presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab in patients with persistent or chronic primary immune thrombocytopenia, a rare immune-mediated bleeding disorder.

Findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes, were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management.

NeuroBo Pharmaceuticals, Inc. announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models.

Gan & Lee Pharmaceuticals announced the results of the Phase 1b/2a clinical study of the Company’s independently developed glucagon-like peptide-1 receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins’ preclinical studies in poster presentations at the American Diabetes Association’s（ADA’s）84th Scientific Sessions.

Novotech, a global full-service clinical Contract Research Organization specializing in partnering with biotech companies to expedite the development of cutting-edge therapeutics across all phases, has published a leading industry report, Liver Cancer - Global Clinical Trial Landscape.